Keywords: b-ms, astrazeneca, collaborate, diabetes, drug, development, program
B-MS and AstraZeneca to collaborate on diabetes drug development program
Article | 22 January 2007
US pharmaceutical major Bristol-Myers Squibb and its Anglo-Swedish counterpart AstraZeneca say that they have entered into an agreement to develop ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
